Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alpha
- 20 February 2007
- Vol. 109 (6) , 1097-1105
Abstract
BACKGROUND: Nuclear p53 and retinoblastoma protein (pRb) were reported to be poor prognostic indicators for transitional cell carcinoma of the bladder. The authors sought to determine the prognostic value of nuclear p53 and pRb in superficial bladder transitional cell carcinoma patients who were treated with intravesical bacille Calmette‐Guerin (BCG) or BCG with interferon‐alpha (IFN‐α).METHODS: A prospective histological review was performed for 80 superficial bladder transitional cell carcinoma patients who underwent postresection intravesical regimes of BCG (81mg, n = 33 or 27 mg, n = 20) or BCG (27 mg) with IFN‐α (n = 27), and followed for a mean of 4.5 years. Hematoxylin and eosin (H & E) and immunoperoxidase staining were performed on tissue sections. Nuclear p53 and pRb immunoreactivity were assessed semiquantitatively, by using a combination of staining extent and intensity, to categorize overexpression or underexpression. Data were analyzed by using chi‐square analysis, multiple logistic regression, and Kaplan‐Meier curves.RESULTS: pRb expression was not associated with patient outcome after BCG‐alone therapy, but pRb underexpression was significantly associated with BCG nonresponse and tumor recurrence (P = .047) after BCG and IFN‐α (BCG + IFN‐α) therapy. Low‐grade tumors were associated with pRb overexpression, with or without nuclear p53 underexpression (P = .019; P = .043, respectively). p53 expression alone or in combination with pRb expression had no significant relation with tumor response to BCG alone or BCG + IFN‐α with respect to recurrence, progression, or cancer‐specific death.CONCLUSIONS: Nuclear pRb underexpression may be predictive of nonresponse and cancer recurrence after intravesical BCG + IFN‐α therapy. Nuclear p53 expression or its combination with pRb expression is not associated with post‐BCG clinical outcome, so p53 expression or p53 with pRb expression should not be used to influence decisions concerning BCG‐alone or BCG + IFN‐α therapy. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic Factors in Stage T1 Grade 3 Bladder Cancer Survival: The Role of G1–S Modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and Proliferation Index (ki67-MIB1)European Urology, 2004
- Pretreatment p53 Nuclear Overexpression as a Prognostic Marker in Superficial Bladder Cancer Treated with Bacillus Calmette–Guérin (BCG)European Urology, 2004
- Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladderEuropean Journal of Surgical Oncology, 2003
- THE PREDICTIVE VALUE OF MUSCULARIS MUCOSAE INVASION AND p53 OVER EXPRESSION ON PROGRESSION OF STAGE T1 BLADDER CARCINOMAJournal of Urology, 2001
- CORRELATION AND PROGNOSTIC SIGNIFICANCE OF p53, p21 WAF1/CIP1 AND Ki-67 EXPRESSION IN PATIENTS WITH SUPERFICIAL BLADDER TUMORS TREATED WITH BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPYJournal of Urology, 1999
- CORRELATION BETWEEN p53 OVER EXPRESSION AND RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY IN A HIGH RISK SELECT POPULATION OF PATIENTS WITH T1G3 BLADDER CANCERJournal of Urology, 1998
- An immunohistochemical study of p53 protein in ovarian mucinous neoplasmsPathology, 1996
- An immunohistochemical study of p53 protein in cervical intraepithelial neoplasia and squamous cell carcinomaPathology, 1996
- p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection.Journal of Clinical Pathology, 1995
- Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancerJournal of Cancer Research and Clinical Oncology, 1995